Navegando por Palavras-chave "posaconazole"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment
    (Informa Healthcare, 2011-04-01) Queiroz-Telles, Flavio; Nucci, Marcio; Colombo, Arnaldo Lopes [UNIFESP]; Tobon, Angela; Restrepo, Angela; Univ Fed Parana; Universidade Federal do Rio de Janeiro (UFRJ); Universidade Federal de São Paulo (UNIFESP); Corp Invest Biol
    Implantation or subcutaneous mycoses are a frequent health problem in Latin American countries and other tropical and subtropical areas. Although such infections rarely cause disseminated or invasive disease, they have an important impact on public health, and timely diagnosis and appropriate treatment remain important. Although some implantation mycoses are found in immunocompromised persons, the immunocompetent population is the principal target in Latin America. Most etiologic agents are found in soil, vegetation, and decaying matter in tropical, subtropical, and humid environments and infection is commonly the result of penetrating injury. Infections primarily occur (1) among low socioeconomic groups, (2) among those living in rural areas or involved in farming, hunting, or other outdoor activities, and (3) particularly among adult men. This review focuses on the epidemiology of the most clinically significant implantation mycoses in Latin America, i.e., sporotrichosis, eumycetoma, chromoblastomycosis, subcutaneous phaeohyphomycosis, subcutaneous zygomycosis, and lacaziosis. Main epidemiologic findings, clinical manifestations, diagnosis, and treatment options are also discussed.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values
    (Amer Soc Microbiology, 2018) Espinel-Ingroff, A.; Turnidge, J.; Alastruey-Izquierdo, A.; Dannaoui, E.; Garcia-Effron, G.; Guinea, J.; Kidd, S.; Pelaez, T.; Sanguinetti, M.; Meletiadis, J.; Botterel, F.; Bustamante, B.; Chen, Y. -C.; Chakrabarti, A.; Chowdhary, A.; Chryssanthou, E.; Cordoba, S.; Gonzalez, G. M.; Guarro, J.; Johnson, E. M.; Kus, J. V.; Lass-Floerl, C.; Linares-Sicilia, M. J.; Martin-Mazuelos, E.; Negri, Clara Ezequiel [UNIFESP]; Pfaller, M. A.; Tortorano, A. M.
    Estimating epidemiological cutoff endpoints (ECVs/ECOFFS) may be hindered by the overlap of MICs for mutant and nonmutant strains (strains harboring or not harboring mutations, respectively). Posaconazole MIC distributions for the Aspergillus fumigatus species complex were collected from 26 laboratories (in Australia, Canada, Europe, India, South and North America, and Taiwan) and published studies. Distributions that fulfilled CLSI criteria were pooled and ECVs were estimated. The sensitivity of three ECV analytical techniques (the ECOFFinder, normalized resistance interpretation [NRI], derivatization methods) to the inclusion of MICs for mutants was examined for three susceptibility testing methods (the CLSI, EUCAST, and Etest methods). The totals of posaconazole MICs for nonmutant isolates (isolates with no known cyp51A mutations) and mutant A. fumigatus isolates were as follows: by the CLSI method, 2,223 and 274, respectively